A new drug enters the evaluation process. For patient organizations, this can immediately raise questions. What does this mean for patients? And what role can a patient organization play?
During this review process, certain new, and often expensive, medications are evaluated by the Dutch Healthcare Institute (Zorginstituut Nederland) before they can be reimbursed. Patients’ knowledge and experiences can provide valuable insights into what a treatment actually means for them in practice. But when can patient representatives contribute their knowledge and experience to this process? Who should you approach, and how do you go about it? There is a great deal of information available on the referral process, but the answers to precisely these practical questions are not always easy to find.

That is why FAST is developing an interactive guide for patient organisations, specifically focusing on the ‘sluis’ process. It is a navigation tool based on real-world questions. By making data, knowledge and experience more accessible and providing patient organisations with guidance through this complex process, we aim to better enable them to participate meaningfully and sit at the table as equal partners.

From information to practical action
A topic such as the ‘sluis’ cannot be discussed entirely without jargon and policy language. However, simply explaining how the system works is not enough. That is why the interactive guide links information to practical courses of action. For each stage, the guide shows what happens, what this means for a patient organisation, and what options are available for taking action. Explanatory boxes, discussion cards, checklists, useful links and other practical resources are provided to assist with this.

This not only provides insight into the referral process, but also offers practical guidance on how to organise and incorporate patient input at relevant stages.
Developing in collaboration with patient organisations. The initial draft of the guide was discussed with a group of patient representatives. Their experiences and suggestions helped to refine the structure. The content and format were then further developed. Lysiac is contributing its expertise as a subject matter specialist. In the autumn, we will finalise the content and visual design of the first module. We will then present it to the patient panel once again. If this test proves successful, we will develop the remaining modules. Later this year, we will test the complete guide once more with a wider group of representatives from patient organisations.

A landscape in flux
Policy on medicines is also constantly evolving. With initiatives such as the development of the Future-Proof Medicines System, processes may change in the future. That is why we are designing the guide to be modular, so that it can adapt to changes in policy and practice.
FAST aims to help remove bottlenecks relating to the development of and access to innovative therapies. In a complex process such as the ‘sluis’, it can be difficult for patient organisations to find the right information and the right organisation at the right time.
The guide does not make the ‘sluis’ any less complex. However, those who are familiar with the playing field will find it easier to navigate.